Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 3:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 687 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Vector Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria

NCT05581641
View directory record Official record
Conditions
Malaria
Interventions
BNT165b1, Placebo
Biological · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
5
States / cities
Tempe, Arizona • Baltimore, Maryland • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Oct 23, 2026, 3:12 AM EDT
Withdrawn No phase listed Observational

Treatment of Leishmaniasis With Impavido® (Miltefosine): Higher-Weight Patient Registry

NCT02429505
View directory record Official record
Conditions
Leishmaniasis
Interventions
Miltefosine
Drug
Lead sponsor
Knight Therapeutics (USA) Inc
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Poolesville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2020 · Synced Oct 23, 2026, 3:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine

NCT01436422
View directory record Official record
Conditions
Dengue
Interventions
TetraVax-DV Vaccine - Admixture TV003, TetraVax-DV Vaccine - Admixture TV005, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
3
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Aug 20, 2015 · Synced Oct 23, 2026, 3:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Malaria Challenge in Healthy Volunteers

NCT01500980
View directory record Official record
Conditions
Malaria
Interventions
P. falciparum infection, Chloroquine, Primaquine
Biological · Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 13, 2012 · Synced Oct 23, 2026, 3:12 AM EDT
Completed Phase 1 Interventional

Phase I Study of HIV Adenoviral Vector Vaccine in Healthy Subjects Using Needle or Biojector Injection

NCT00709605
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVADV014-00-VP
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 23, 2026, 3:12 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Clinical Trial)

NCT04998396
View directory record Official record
Conditions
Canavan Disease
Interventions
AAV9 BBP-812
Biological
Lead sponsor
Aspa Therapeutics
Industry
Eligibility
Up to 30 Months
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
4
States / cities
Oakland, California • Chicago, Illinois • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 23, 2026, 3:12 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Lyme Test Indication Combinations (LyTIC) Study

NCT03201042
View directory record Official record
Conditions
Lyme Disease
Interventions
PCR based assay, Serology based assay, Tcell based assay
Diagnostic Test
Lead sponsor
Oxford Immunotec
Industry
Eligibility
5 Years and older
Enrollment
410 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
60
States / cities
Redding, California • New London, Connecticut • Norwalk, Connecticut + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 23, 2026, 3:12 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

AAV Gene Therapy Study for Subjects with PKU

NCT04480567
View directory record Official record
Conditions
Phenylketonuria (PKU)
Interventions
BMN 307
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
15 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Tampa, Florida • Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Oct 23, 2026, 3:12 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Efficacy, Immunogenicity and Safety in a Sporozoite Challenge Model of a Fractional Booster Dose of GSK Biologicals' Candidate Malaria Vaccine Administered to Previously Vaccinated Healthy Malaria-naïve Adults

NCT03824236
View directory record Official record
Conditions
Malaria
Interventions
RTS,S/AS01E (SB257049)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 14, 2020 · Synced Oct 23, 2026, 3:12 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Disulfiram: A Test of Symptom Reduction Among Patients With Previously Treated Lyme Disease

NCT03891667
View directory record Official record
Conditions
Fatigue, Quality of Life
Interventions
Disulfiram
Drug
Lead sponsor
Research Foundation for Mental Hygiene, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Oct 23, 2026, 3:12 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study of VMP001 and AS01B (Adjuvant Formulation) in Healthy Malaria-Naïve Adults

NCT01157897
View directory record Official record
Conditions
Malaria, Plasmodium Vivax
Interventions
VMP001, P. vivax sporozoite challenge
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Oct 23, 2026, 3:12 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy, Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Evaluating Different Dose Schedules in a Sporozoite Challenge Model in Healthy Malaria-naïve Adults

NCT03162614
View directory record Official record
Conditions
Malaria
Interventions
RTS,S/AS01E, RTS,S/AS01B, Sporozoite-infected mosquitoes challenge.
Biological · Procedure
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Oct 23, 2026, 3:12 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Human Immune Responses to Yellow Fever Vaccination

NCT00694655
View directory record Official record
Conditions
Yellow Fever
Interventions
Yellow Fever Vaccine, Leukapheresis, Fine-needle aspiration (FNA)
Biological · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years to 45 Years
Enrollment
239 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2024
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 23, 2026, 3:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Zika Virus Purified Inactivated Vaccine (ZPIV) Accelerated Vaccination Schedule Study

NCT02937233
View directory record Official record
Conditions
Zika
Interventions
Zika Virus Purified Inactivated Vaccine, Placebo
Biological · Other
Lead sponsor
Kathryn Stephenson
Other
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 23, 2018 · Synced Oct 23, 2026, 3:12 AM EDT
Recruiting Phase 1 Interventional

A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy

NCT07137338
View directory record Official record
Conditions
Dilated Cardiomyopathy (DCM)
Interventions
RP-A701 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, BCL2-associated Athanogene 3 (BAG3)
Genetic
Lead sponsor
Rocket Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
San Diego, California • Rochester, Minnesota • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 23, 2026, 3:12 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Turnover of Antigen Specific Lymphocytes and Monocytes After Immunization With the 17D Yellow Fever Vaccine

NCT01290055
View directory record Official record
Conditions
Yellow Fever
Interventions
Yellow fever vaccine, Deuterium (70% enriched 2H2O) labeled water
Biological · Other
Lead sponsor
Sri Edupuganti
Other
Eligibility
18 Years to 45 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 23, 2026, 3:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of a Vaccine (DENV-1 PIV) to Prevent Dengue Disease

NCT01502735
View directory record Official record
Conditions
Dengue Fever
Interventions
DENV-1 PIV, 2.5 µg, DENV-1 PIV, 5 µg
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 22, 2015 · Synced Oct 23, 2026, 3:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Experimental Vaccine for Prevention of Ebola Virus Infection

NCT00374309
View directory record Official record
Conditions
Ebola Hemorrhagic Fever, Ebola Virus Disease, Ebola Virus Vaccines, Envelope Glycoprotein, Ebola Virus, Filovirus
Interventions
VRC-EBOADV018-00-VP
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 23, 2026, 3:12 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults

NCT03342898
View directory record Official record
Conditions
Dengue
Interventions
YF-17D, TDV, Placebo
Biological · Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 60 Years
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
11
States / cities
Mobile, Alabama • Pomona, California • Meridian, Idaho + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 23, 2026, 3:12 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety Study of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase to Treat Pompe Disease

NCT00976352
View directory record Official record
Conditions
Pompe Disease
Interventions
rAAV1-CMV-GAA (study agent) Administration, RMST
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
2 Years to 18 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 14, 2018 · Synced Oct 23, 2026, 3:12 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study of AT-752 in Healthy Subjects in a Dengue Human Challenge Model

NCT05366439
View directory record Official record
Conditions
Dengue
Interventions
AT-752, Placebo Comparator
Drug
Lead sponsor
Atea Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2023 · Synced Oct 23, 2026, 3:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis

NCT03010228
View directory record Official record
Conditions
Lyme Borreliosis, Nervous System
Interventions
VLA15 with Alum, VLA15 without Alum
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 39 Years
Enrollment
179 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
4
States / cities
La Mesa, California • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Oct 23, 2026, 3:12 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Phase II Tularemia Vaccine Comparison

NCT01150695
View directory record Official record
Conditions
Tularaemia
Interventions
Placebo, Undiluted Francisella tularensis live attenuated vaccine
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
228 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
5
States / cities
Decatur, Georgia • Iowa City, Iowa • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Oct 23, 2026, 3:12 AM EDT
Completed No phase listed Observational

Zika Virus and Related Arbovirus Infections in Deferred Blood Donors (ZVADD)

NCT02794181
View directory record Official record
Conditions
Zika Virus, Dengue Virus, Chikungunya Virus Infections
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Oct 23, 2026, 3:12 AM EDT